# Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease

> **NCT01685515** · PHASE1 · COMPLETED · sponsor: **Yogen Saunthararajah** · enrollment: 25 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Oral Decitabine and Tetrahydrouridine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01685515
- **Lead sponsor:** Yogen Saunthararajah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01685515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01685515, "Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01685515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*